close

Enter

Log in using OpenID

Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market

embed
Multiple myeloma (MM) refers to a clonal plasma cell malignant neoplasm that is observed in the soft, spongy tissue of the bone marrow. The plasma cells are a crucial part of the immune system, which helps to fight against various types of infection
Global B-cell Maturation Antigen
(BCMA) Targeted Therapies Market GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK,
AND OPPORTUNITY ANALYSIS, 2018-2026
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market – Overview
Recurrence of multiple myeloma has been a highly prevalent health condition, which requires novel and effective
immunotherapeutic treatment. According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is
estimated to be around 120,000 cases per year, with a global prevalence of over one million cases. B-cell maturation antigen
(BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a
very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three
major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells),
bispecific antibodies, and antibody drug conjugates (ADCs). These advanced therapies are expected to improve the survival
rate of multiple myeloma patients.
Market Dynamics
Increasing prevalence of multiple myeloma is expected to favor the B-cell maturation antigen (BCMA) targeted therapies
market worldwide. According to the American Cancer Society, U.S., in 2016, the lifetime risk for multiple myeloma was
around 1 in 143 people, with an estimated 30,280 adults (17,490 men and 12,790 women) diagnosed with multiple myeloma.
The mortality rate of the disease was estimated to be 12,590 (6,660 men and 5,930 women) in 2016. Key players are actively
involved in the development of immunotherapies targeting BCMA for the treatment of multiple myeloma, the demand for
which is expected to increase, This in turn, is expected to boost development of novel treatments for relapsed or refractory
myeloma.
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market
Taxonomy:
By Product Type:
●
Antibody Drug Conjugates
●
CAR-T Cells
●
Bispecific Antibodies
By Indication:
●
Acute Lymphoblastic Leukemia
●
Multiple Myeloma
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/190
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market: Key Players
●
Celgene Corporation
●
GlaxoSmithKline plc.
●
Novartis AG
●
Juno Therapeutics
●
Gilead Sciences. Inc
●
Amgen Inc
●
Affimed N.V
●
Poseida Therapeutics, Inc.
●
Autolus Ltd
View this report @
https://www.coherentmarketinsights.com/market-insight/bcma-targeted-therapies-market-190
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
ABOUT US
Coherent Market Insights is a global market intelligence and consulting organization
focused on assisting its plethora of clients achieve transformational growth by helping
them make critical business decisions. We are headquartered in India, with an office at
the global financial capital in the U.S. Our client base includes players from across all
business verticals in over 150 countries worldwide. We are uniquely positioned to help
businesses around the globe deliver practical and lasting results through various
recommendations about operational improvements, technologies, emerging market
trends and new working methods. We offer both customized and syndicated market
research reports that help our clients create visionary growth plans to provide traction to
their business. We meticulously study emerging trends across various industries at both
the global and regional levels to identify new opportunities for our clientele.
SERVICES
INDUSTRY ANALYSIS
CUSTOMIZED
RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE
SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC
STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
SECTOR COVERAGE
Healthcare
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL IMAGING
PHARMACEUTICAL
MEDICAL DEVICES
Chemicals & Materials
Bulk Chemicals
Advanced
Materials
Speciality and Fine Chemicals
Green Chemicals
Food Ingredients
© Coherent market Insights. All Rights Reserved
Cosmetic Ingredients
Polymers & Resins
ABOUT COHERENT MARKET INSIGHTS
KEY STATS
RESEARCH SOLUTIONS
FEASIBILITY
STUDIES
GLOBAL
REPORTS
100+
Insights Published Per Year
150+
Consulting Projects Till Date
125+
Clients Worldwide Per Year
110+
COUNTRY
ANALYSIS
CONSULT
PROJECTS
SURVEY
RESEARC
H
EXCEL
FORECAST
DATABASE
CUSTOMIZED
SOLUTIONS
COMPETITIVE
ASSESSMENT
TECHNOLOGY
SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and
food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across
various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our
clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained
growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein.
© Coherent market Insights. All Rights Reserved
To k no w mor e abo ut us , v is it o ur w eb site:
w ww.coh er en tmark etins ig hts.com
THANK YOU
© Coherent market Insights. All Rights Reserved
F or s ales q ueries o r new top ics email u s o n :
s [email protected] er en tmark etins ig hts .co m
Fo r o th er q uer ies co n tact:
Mr. Sh ah
( Man ag er - Bus iness D ev elo pment)
Co herent Mark et Ins ig hts
s [email protected] er en tmark etins ig hts .co m
+1 -2 06 -7 0 1- 67 02
1/--pages
Report inappropriate content